This study focuses on patients with advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs) who have previously received treatment with platinum-based chemotherapy. The main treatment being investigated is tarlatamab, which will be compared to standard chemotherapy treatments including oxaliplatin, dacarbazine, docetaxel, temozolomide, irinotecan, and fluorouracil. Some patients may also receive immunotherapy medications like atezolizumab, nivolumab, or pembrolizumab.
The purpose of this research is to evaluate how well tarlatamab works compared to standard chemotherapy treatments in treating this type of cancer. The study will measure how long patients survive after receiving treatment. The medication will be given through an infusion into a vein.
During the study, doctors will monitor patients’ response to treatment using imaging scans and blood tests. They will also track any side effects that occur and evaluate patients’ quality of life using questionnaires. The study is expected to last for approximately 24 months per patient.
France 
